Chris Lord – Exploiting synthetic lethality in the design of new therapeutic approaches for cancer
VHIO -”la Caixa” Foundation SCIENTIFIC SEMINARS SERIES
- Speaker: Chris Lord, Deputy Head of Division, Team Leader of the CRUK Gene Function Laboratory and Professor of Cancer Genomics in the Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research, London.
- Talk title: Exploiting synthetic lethality in the design of new therapeutic approaches for cancer
- Date & time: Friday 2nd October, 12:00h
- Host: Violeta Serra, Principal Investigator of VHIO´s Experimental Therapeutics Group
Identifying, understanding and exploiting PARP inhibitor and other synthetic lethal effects remains the focus of Prof. Lord’s work. This work includes efforts to identify the molecular features that predict response to therapy, identifying drug combination strategies that can maximise efficacy and understanding how drug resistance emerges. In addition to focussing on using a synthetic lethal approach to target BRCA-gene mutant cancers, Prof. Lord’s work also focusses on identifying and understanding synthetic lethal effects associated with other DNA repair defective cancers and well as those with E-cadherin, Rb or SWI/SNF defects.